Trial reportLasers in medical science2025
Photobiomodulation therapy and 5% minoxidil in female pattern hair loss: a case series focusing on hair growth phases over a shorter timeframe.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Clinical Application of a New Near-Infrared Light-Emitting Diode with Broader Spectrum for Skin Rejuvenation and Hair Growth Enhancement".Aesthetic plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFemale pattern hair loss (FPHL) is a major concern for women experiencing hair thinning. While minoxidil 5% (MIN) is a medically approved treatment and photobiomodulation therapy (PBMt) has shown effectiveness in stimulating hair growth, treatments typically last 24 weeks. This study aimed to evaluate the effects of combining PBMt with topical MIN for treating FPHL within a shorter 12.5-week timeframe, focusing on hair growth phases.
methodsNine women aged 30 to 50 years with FPHL participated. They applied MIN twice daily to the scalp throughout the treatment period. In the clinic, hair was sectioned, and one side of the scalp was randomly assigned to receive 25 sessions of red laser (100 mW, 4 J/point), delivered at 15 evenly spaced points. Treatments were administered twice a week, while the opposite side received sham irradiation. Standardized photographs, a quality of life (QoL) questionnaire, and phototrichograms were used to evaluate the outcomes.
resultsBoth the MIN and PBMt + MIN groups showed significant improvements in QoL scores and hair density. Additionally, both groups experienced increased hair density and a higher percentage of hairs in the anagen phase. Remarkably, the PBMt + MIN group exhibited a significantly greater reduction in telogen-phase hairs.
conclusionThese findings suggest that PBMt may enhance MIN therapy for FPHL, particularly in reducing telogen-phase hair counts within a shorter treatment period. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41369788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.